Matthew McNatt, Ph.D.Scientific Advisor
Dr. McNatt has over 15 years of scientific research within diverse backgrounds ranging from Biochemistry, Molecular Biology, Cell Biology, Virology, Immunology, and Synthetic Biology. Dr. McNatt has transitioned through multiple scientific fields and is able to quickly assimilate and teach scientific concepts to support the legal council.
Matthew McNatt, Ph.D. is a scientific advisor in the New York office of Haug Partners. He was an entrepreneurial scientist who cofounded and was the Chief Science Officer of a fledgling biotech company. The company was focused on developing cell-lines to shorten the manufacturing timeline and to increase the titer of biologics with an emphasis on antibodies. As the Chief Science Officer, Dr. McNatt authored the patent to navigate around prior art and connected with advisors, collaborators and potential investors. Dr. McNatt leverages his business background to match the business needs of the client. Dr. McNatt earned his B.Sc. in Biochemistry from Michigan State University, a Ph.D. in Molecular and Cellular Biology from the University of Colorado, and a Postdoctoral Fellowship investigating HIV-1 at the Aaron Diamond Aids Research Center. He has special interest in the growing field of biologics and biosimilars where he can apply his 3+ years of litigation experience and his extensive 15+ years of research to evaluate the science and provide insightful counsel.
PUBLICATIONS: ACADEMIC JOURNAL ARTICLES
- McNatt, Ph.D., Matthew, et al. “Vaccine Design Will Likely Determine the Success of Each COVID-19 Vaccine.” Haug Partners, 11 Nov. 2020, www.haugpartners.com/article/vaccine-design-will-likely-determine-the-success-of-each-covid-19-vaccine/.
- Hatziioannou T, Del Prete G, Keele BF, Estes JD, McNatt MW, Bitzegeio J, Raymond A, Rodriquez A, Schmidt F, Trubey CM, Smedley J, Piatak M, KewalRamani VN, Lifson JD, Bieniasz PD. HIV-1 induced AIDS in monkeys, Science 2014 June 20; 344(6190):1401-5.
- McNatt MW, Zang T, and Bieniasz P. Vpu binds directly to Tetherin and displaces it from nascent virions. PloS Pathogens, April 2013.
- Zhang F, Landford WN, Ng M, McNatt MW, Bieniasz PD, Hatziioannou T. SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. PLoS Pathogens, May, 2011.
- Yang H, Wang J, Jia X, McNatt MW, Zang T, Pan B, Meng W, Wang HW, Bieniasz PD, Xiong Y. Structural insight into the mechanism of enveloped virus tethering by tetherin. PNAS, Oct 26, 2010; 107(43):18428-32.
- David Perez-Caballero, Trinity Zang, Alaleh Ebrahimi, Matthew W. McNatt, Devon A. Gregory, Marc C. Johnson, and Paul D. Bieniasz. Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells. Cell, October 30, 2009.
- McNatt, M.W., Zang, T., Hatziioannou, T., Barlett, M., Fofana I. B., Johnson W., Niel, S. J. D., Bieniasz, P. D. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathogens, Feb. 2009.
- Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M., Hatziioannou T, Bieniasz PD. Broad-Spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol. 2008 Nov 26.
- McNatt, M.W., McKittrick, I., West M., and Odorizzi, G. Direct binding to Rsp5 mediates ubiqutin-independent sorting of Sna3 via the multivesicular body pathway. Mol. Bio. Cell, 2007 Feb;18(2):697-706.
- Ludlam, A.V., McNatt, M.W. and Kaguni, J.M. (2001) Essential amino acids of Escherichia coli DnaC protein in an N-terminal domain interact with DnaB helicase. J. Biol. Chem. 276, 27345-27353.
- Oral Presentations
- McNatt, M.W., Zang, T., Bieniasz, P.D. (2012). Vpu directly interacts with Tetherin and displaces it from sites of viral assembly. Aaron Diamond AIDS Research Center Scientific Advisory Board meeting.
- McNatt, M.W., Zang, T., Bieniasz, P.D. (2010). Displacement of Tetherin from sites of HIV-1 assembly at the plasma membrane by Vpu. Retrovirology Meeting, Cold Spring Harbor Laboratory.
- McNatt, M.W. and Odorizzi, G. (2003). Investigating the bifurcation in multivesicular body formation. Rocky Mountain Yeast Group.
- Poster Presentations (selected)
- McNatt, M.W. and Bieniasz, P.D. (2013). The mechanism of antagonism of Tetherin by the HIV-1 Vpu protein. Center for Digestive Diseases and Infectious Disease Biology Retreat.
- McNatt, M.W., Zang, T., Bieniasz, P.D. (2012). Vpu directly interacts with Tetherin and displaces it from sites of viral assembly. Keystone Symposia (Frontiers in HIV Pathogenesis, Replication and Eradication).
- McNatt, M.W., Zang, T., Bieniasz, P.D. (2011). Vpu directly interacts with Tetherin and displaces it from sites of viral assembly. Rockefeller University Infectious Disease Biology Retreat.
- McNatt, M.W., Zang, T., Bieniasz, P.D. (2009). Antagonism of Tetherin by Vpu in the absence of Tetherin downregulation. Retrovirology meeting, Cold Spring Harbor Laboratory.
- McNatt, M.W., West, M., Odorizzi, G. (2004). Two distinct types of vesicles are formed by the multivesicular body in yeast. Lysosomes, Gordon Research Conference Proctor Academy.
- McNatt, M.W. and Odorizzi, G. (2004). Investigating multivesicular body formation and sorting. Golgi Apparatus, Keystone Symposia. Conference Assistant
- McNatt, M.W. and Odorizzi, G. (2003). Two distinct types of vesicles are formed by the multivesicular body in yeast. Yeast Cell Biology Meeting, Cold Spring Harbor Laboratory.
- McNatt, M.W. and Odorizzi, G. (2003). Ubiquitin dependent and independent trafficking through the multivesicular body pathway in yeast. Molecular, Cellular and Developmental Biology Departmental Retreat.
- Award: Mathilde Krim Fellow (2 years; $125,000)
- From: American Foundation for AIDS Research (amfAR)
- Bestowed: January 2011
- Project title: Vpu counteraction of Tetherin
- University of Colorado, (Ph.D., Molecular and Cellular Biology)
- Michigan State University, (B.Sc. Biochemistry)
- Golden Key International Honour Society